The CoApt Valve™

Adhering to the philosophy of “One Medicine, One Health, One World”, the CoApt Valve® is being developed for both canine and human mitral valve disease. It is designed to provide a minimally invasive solution for severe mitral and tricuspid valve disease, significantly extending life expectancy and quality of life.

Successful testing in a naturally occuring animal model acts as a precursor to migrating the technology into the human marketplace.

Latest News

    • Eliachar Technologies Development located in Haifa Israel, a leading product development engineering firms agrees to oversee product design and development

    • The Electrospinning Company located in Didcot UK, is signed to manufacture the valve’s apron

    • ViVitro Labs, a world-renowned cardiovascular device testing laboratory located in Victoria Canada and specializing in cardiac pulse duplication and durability testing signs on

    • QTest Labs, a CRO that specializes in efficacy, cardiovascular safety and risk assessment for pharmaceutical and medical device development is retained

    • LifeTec Group, Eindhoven Netherlands, a preclinical CRO and the home of the Cardiac BioSimulator signs on

    • Cardiovascular Research Foundation, a state-of-the-art cardiac research center located in Orangeburg, NY dedicated to identifying, developing, and promoting the latest advancements in the treatment of heart disease becomes part of our team

    • Valve frame is a self expanding nitinol frame

    • Valve material is an electrospun polymer (50 microns in thickness). Designed for superior flexibility, durability and promotes endothelializtion

    • The low-profile valve design allows for loading into a 9.5 Fr catheter (2.5 mm internal diameter), for delivery

    • The anchor system is comprised of three nitinol trebled anchors attached to flexible polymeric monofilament tethers

    • Complete system prototype is comprised of a table mount, transcatheter guiding device, catheter guiding sheath, and the newly designed CoApt Valve®

    • The CoApt Valve™ achieved positive results in benchtop post duplicator testing

    • CoApt Valve™ transcatheter implantation in a Cardiac BioSimulator: (LifTec Group, Eindhoven Netherlands, May & September 2023) provided positive proof of concept in an explanted pig heart model

    • CoApt Valve™ transcatheter implantation in purpose-bred dogs: (CRF, Orangeburg New York, December 2023). We deployed the first-in-the world transvenous transcatheter mitral valve in live dogs. Results showed excellent valve functioning without any thromboembolic complications over the course of the 30 day study

    • We are now scheduling our veterinary clinical studies stage which will also serve as a naturally occuring animal model of the human disease as part of our “One Medicine” philosophy

    • George Kramer, DVM/DACVIM has been chosen by Lifescience Intelligence (LSI) as a global innovator to speak at LSI Europe, September 7-11, 2025 in London. He will be discussing the CoApt Valve™’s potential as a transcatheter device designed to treat severe mitral and tricuspid valve disease in humans without the need for open-heart surgery. Under the philosophy of “One Medicine, One Health, One World”, the CoApt Valve™ is being developed for both canine and human mitral valve disease.

    • Dr. Kramer will also be participating in the American College of Veterinary Internal Medicine’s on-demand series of presentations running from June through October 2025. He will be speaking on Transcatheter Mitral and Tricuspid Valve Therapies.

    • Neocor’s CoApt Valve™ wins the Shark Tank competition at the Georgia MedTech Innovation Summit in Tbillisi, Georgia, besting 25 other entries

See the Live Implantation of the CoApt Valve in a Beating Sheep Heart

June 20, 2025-ACVIM Forum, Louisville, KY

See Dr. Kramer’s Presentation at LSI London, September 2025

Dr. Kramer Presenting at LSI USA 2026

Our Mission is One Medicine, One Health, One World in Developing a Solution for Severe Mitral and Tricuspid Valve Disease

  • Mitral Valve Disease is the most common valve disease in both canines and man, with very similar histopathology and natural history in both species

  • Each year there are approximately 2 million dogs in the United States that require therapy for Degenerative Mitral Valve Disease alone; as well as 2%-3% of the world’s human population including 7.8 million people in the U.S. alone and 14% of the elderly community

  • If left untreated, the disease leads to congestive heart failure, and death in both species

  • There is no medical cure for the disease, the only definitive treatment is open heart mitral valve repair, which in the veterinary industry can cost upwards of $50,000 per case

  • The total U.S. cost per annum of human mitral valve disease is estimated at $7.6 billion for symptomatic cases and $5.6 billion for asymptomatic cases

The CoApt Valve™ is the Solution

  • A transcatheter intracardiac device designed for placement within incompetent atrioventricular valve apparatus (mitral or tricuspid)

  • Reduces or eliminates the regurgitant jet associated with the incompetent valve, without open heart surgery

  • Designed to work in cooperation with the native valve leaflets without disrupting the important connection between the atrial annulus and the ventricle

  • Installed in humans via catheterization of the transfemoral vein without

    opening the chest

  • Can be performed by any trained interventional cardiologist

  • The CoApt Valve™ system is patented and trademarked

Connect With Us

Discover how NeoCor is attempting to leverage veterinary medical devices into successful treatments for humans. Reach out to explore our groundbreaking solutions and elevate the care you provide to your patients.